^
    Back
    Association details:
    Biomarker:MGMT unmethylation
    Cancer:Glioma
    Drug:Focus V (anlotinib) (Multi-tyrosine kinase inhibitor)
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: C3 – Early Trials
    Source:
    ASCO 2023
    Title:

    Anlotinib for patients with newly diagnosed glioblastoma with unmethylated MGMT promoter: An open-label, single-center, phase 2 clinical trial.

    Published date:
    05/25/2023
    Excerpt:
    This preliminary analysis suggested that anlotinib had promising efficacy and favorable tolerance as treatment of newly diagnosed GBM with unmethylated MGMT promoter.
    DOI:
    10.1200/JCO.2023.41.16_suppl.e14039